Recently, the Food and Drug Administration (FDA) has approved tazemetostat, an EZH2 inhibitor, for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for radical resection. The gene discussed is EZH2; the disease is epithelioid sarcoma.